Sandoz Group AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
Clinical Trials
139
Trial Phases
5 Phases
Drug Approvals
52
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (133 trials with phase data)• Click on a phase to view related trials
An Efficacy and Safety Study With Integrated Pharmacokinetics (PK) and Pharmacodynamic (PD) Assessment to Compare the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Biological: CYB704Biological: Ocrevus-EUBiological: Ocrevus-US
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 518
- Registration Number
- NCT06847724
- Locations
- 🇵🇱
Sandoz Investigational Site, Warsaw, Poland
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
- Conditions
- Advanced (unresectable/metastatic) melanoma
- Interventions
- Drug: JPB898 (Induction and Maintenance)Drug: Opdivo-EU (Induction)Drug: Opdivo-US (Induction)Drug: Yervoy-EU (Induction)Drug: Opdivo-EU (Maintenance)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- H e x a l AG
- Target Recruit Count
- 302
- Registration Number
- 2023-507865-24-00
- Locations
- 🇨🇳
Sandoz Investigational Site, Taoyuan City, Taiwan
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 720
- Registration Number
- NCT06159790
- Locations
- 🇻🇳
Sandoz Investigational Site, Hà Nội, Vietnam
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 318
- Registration Number
- NCT06153238
- Locations
- 🇹🇷
Sandoz Investigational Site, Yüreğir, Turkey
Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 38
- Registration Number
- NCT05887843
- Locations
- 🇨🇦
Sandoz Investigational Site, Toronto, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 28
- Next
News
Major Pharmaceutical Companies Face Surge in Generic Drug Patent Challenges in Early 2025
Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.
Lupin Partners with Sandoz to Commercialize Ranibizumab Biosimilar Across Multiple Global Markets
Lupin Limited has entered into a strategic partnership with Sandoz Group AG to commercialize its biosimilar ranibizumab across the European Union, Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia.
Contract Manufacturing Industry Report Reveals Impact of Global Conflicts and Inflation on Pharmaceutical Production
The 15th edition of the CMO industry analysis uses FDA NDA approvals as the primary performance indicator for contract manufacturing organizations.
Sandoz Plans Generic Semaglutide Launch in Canada with Up to 70% Price Reduction
Swiss generic manufacturer Sandoz plans to launch unbranded semaglutide weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents expire next year.
German Federal Patent Court Revokes Key Xarelto Patent, Opening Door for Generic Competition
The German Federal Patent Court revoked Bayer's crucial Xarelto patent EP 1 845 961 due to lack of inventive step, contradicting its earlier 2024 opinion that assumed the patent's validity.
Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy
Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.
Biocon Races to Launch First Generic Semaglutide in Canada as Wegovy Patents Expire
Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.
Celltrion Advances Pembrolizumab Biosimilar Development as Herceptin Copy Nears European Launch
Celltrion has initiated development of a biosimilar version of Merck's pembrolizumab (Keytruda), starting work 10 years ahead of the drug's patent expiration in June 2028.
Sandoz Invests $1.1 Billion in European Biosimilar Manufacturing Hub to Capture $222 Billion Market Opportunity
Sandoz has broken ground on a $440 million biosimilar manufacturing facility in Brnik, Slovenia, bringing total planned investment in the country to over $1.1 billion by 2029.
Major Pharma Companies Face Massive Revenue Losses as Patent Cliff Hits Key Blockbusters
The pharmaceutical industry is experiencing one of the biggest patent cliffs since 2010, with blockbuster drugs including Merck's Keytruda, BMS's Eliquis, and Johnson & Johnson's Darzalex losing market exclusivity between 2025-2030.